In many cases, people can not figure out ONC201 and TIC10.

Those 2 molecules have very similar structures, if you don’t look closely, you will not see the differences between them.

But only ONC201 is active and effective against cancers, while TIC structure is a mistake made by the creator. 

As the first member of the imipridone class of small molecules, ONC201, with cas number 1616632-77-9, is currently being tested in phase II clinical trials of patients with hematological malignancies and solid tumors. (1)

ONC201 is very useful and has been put into clinical trials for many types of cancer such as Pediatric H3 K27M Gliomas, Adult Recurrent H3 K27M-mutant Glioma, etc (2), so we chemists must get the structures right.

But, because ONC201 and TIC10 are two active small molecules strikingly similar to each other, many people even from the chemical industry did not get the correct chemical structures of each other.

Some very authoritative companies are even mislabeling each other on their websites, including PubChem.

For this wrong information, we even wrote an email to the PubChem administrator to do something about the wrong structure.

But here we have listed the correct structure corresponding to each name as you can see below, so you won’t get them wrong.

So far as we know, the chemical structure of ONC201 originally published by Stahle, et. al. in the patent literature was incorrect.

Listings on many websites [pubchem(3), bocsci(4)] got it wrong.

They labeled the bioactive structure both as TIC10 and ONC201.

We have looked up documents and run 1HNMR to get the right structures for your ref.